|
WO2009094592A2
|
|
Genetic basis of alzheimer's disease and diagnosis and treatment thereof
|
|
WO2009055708A1
|
|
Selection probe amplification
|
|
US2009124514A1
|
|
Selection probe amplification
|
|
US2009087854A1
|
|
Methods for genetic analysis
|
|
WO2009023048A2
|
|
Markers for metabolic syndrome
|
|
US2009006128A1
|
|
Life sciences business systems and methods
|
|
WO2007145992A2
|
|
Genetic basis of treatment response in depression patients
|
|
CA2644475A1
|
|
Markers for addiction
|
|
CN101437960A
|
|
Markers for addiction
|
|
AU2006294565A1
|
|
Methods and compositions for screening and treatment of disorders of blood glucose regulation
|
|
US2007092889A1
|
|
Parkinson's disease-related disease compositions and methods
|
|
US2006223058A1
|
|
In vitro association studies
|
|
WO2006083854A2
|
|
Genetic basis of alzheimer's disease and diagnosis and treatment thereof
|
|
WO2006079101A2
|
|
Associations using genotypes and phenotypes
|
|
US2006211684A1
|
|
Use of alpha-2 adrenergic receptor agonists
|
|
US2006177847A1
|
|
Markers for metabolic syndrome obesity and insulin resistance
|
|
AU2005314408A1
|
|
Markers for metabolic syndrome obesity and insulin resistance
|
|
US2006008834A1
|
|
Life sciences business systems and methods
|
|
US2007003938A1
|
|
Hybridization of genomic nucleic acid without complexity reduction
|
|
CN1950826A
|
|
Methods for genetic analysis
|
